The trial approved by the FDA in the United States has shown that pembrolizumab, an anti-PD-1 inhibitor, is effective in treating advanced cervical cancer patients with PD-L1 positive status (CPISMC 1) and leads to improved outcomes for patients with recurrent or metastatic cervical cancer (83). Here, CD274 is linked to cervical cancer.